Evidence map›Paper›PMID 41497345›Full record

ArticleResearch and practice in thrombosis and haemostasis2025

Heterozygous nonsense

Huan Zhang, Elise J Huisman, Roel van Rhijn, Arthur F Svendsen, Hans Janssen, Nicole van der Wel, Carmen van der Zwaan, Nynke Gillemans, Wilfred F J van IJcken, Marten Hansen and 5 more

Abstract read
In one paragraph

Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Huan ZhangSanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Elise J HuismanDepartment of Pediatric Hematology and Oncology, Erasmus MC Sophia Children's Hospital, University Medical Center, Rotterdam, Netherlands.
Roel van RhijnSanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Arthur F SvendsenSanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Hans JanssenDepartment of Electron Microscopy, Dutch Cancer Institute-NKI, Amsterdam, Netherlands.
Nicole van der WelDepartment of Electron Microscopy, Amsterdam University Medical Center, Amsterdam, Netherlands.
Carmen van der ZwaanSanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Nynke GillemansDepartment of Developmental Biology, Erasmus University Medical Center, Rotterdam, Netherlands.
Wilfred F J van IJckenCore Facility Genomics, Erasmus University Medical Center, Rotterdam, Netherlands.
Marten HansenSanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Marjon H CnossenDepartment of Pediatric Hematology and Oncology, Erasmus MC Sophia Children's Hospital, University Medical Center, Rotterdam, Netherlands.
Sjaak PhilipsenDepartment of Developmental Biology, Erasmus University Medical Center, Rotterdam, Netherlands.
Arie J HoogendijkSanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
Emile van den AkkerSanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
SYMPHONY consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Megakaryocytes and platelets arise from hematopoietic stem and progenitor cells through a tightly regulated process involving various transcription factors, including erythroblast transformation-specific family member FLI1. Pathogenic variants in Objectives: In this study, we describe a patient with a de novo heterozygous nonsense mutation, Methods: Wild-type (WT) FLI1 and FLI1 p.Met100∗ were expressed in Meg01 cells. Bulk RNA sequencing, proteomics, and flow cytometry were performed to assess their functional consequences. Results: Western blot analysis confirmed truncated FLI1 p.Met100∗ protein expression in Meg01 cells. Gene set enrichment analysis revealed that WT FLI1 enhanced megakaryocytic phenotypes, while suppressing erythroid phenotypes, whereas FLI1 p.Met100∗ upregulated both. Flow cytometry confirmed that erythroid markers CD235a and KLF1 were downregulated by WT FLI1 but elevated by FLI1 p.Met100∗. Additionally, WT FLI1 promoted megakaryocyte maturation and adhesion, as evidenced by increased expression of the megakaryocyte marker CD61 and adhesion markers CD34 and CD44. Moreover, we demonstrated through immunoprecipitation that both WT FLI1 and FLI1 p.Met100∗ interact with shared cofactors. Conclusion: Collectively, our findings suggest that FLI1 p.Met100∗ impairs megakaryocyte maturation through a dominant-negative manner, potentially contributing to thrombocytopenia by promoting erythroid features at the expense of proper megakaryocytic development.

Indexed as

FLI1megakaryopoiesisplatelet disorderthrombocytopenia

Identifiers

PMID41497345
PMCPMC12767185

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.